Company news

Faron Pharmaceuticals Oy news in 2024

Faron Pharmaceuticals Oy's news releases, calls and decks from 2024, newest first.

View company

Faron’s Financial Calendar for 2025

December 13, 2024

Faron presents BEXMAB data at ASH Annual Meeting

December 10, 2024

Interactions with UK Regulatory Authorities

December 2, 2024

Positive Phase 2 Interim Results from BEXMAB Trial

November 27, 2024

Targeting Soluble Clever-1 for Autoimmune Diseases

November 11, 2024

Shareholders’ Nomination Board

November 5, 2024

Faron’s Capital Markets Day 2024

October 22, 2024

Faron announces Capital Markets Day

October 7, 2024

Grant of options

August 30, 2024

FDA Grants Fast Track Designation for Bexmarilimab

August 27, 2024

Faron 2024 Half-Year Financial Results

August 27, 2024

Notice of Half-Year Financial Results

August 20, 2024

Traumakine Research Collaboration and DoD Grant

August 13, 2024

Appointment of Chief Financial Officer

August 8, 2024

Faron Appoints Dr. Petri Bono as new CMO

August 6, 2024

Faron Announces Positive FDA Feedback

July 11, 2024

Update on settlement

June 25, 2024

Holding(s) in Company - Replacement

June 25, 2024

New shares registered with Finnish Trade Register

June 20, 2024

Fully subscribed EUR 30.7 million share offering

June 20, 2024

Proposed REX Retail Offer

June 5, 2024

Faron commences a share offering

June 4, 2024

Initial positive data from Phase 2 of BEXMAB

May 20, 2024

Issuance of warrants

May 17, 2024

Founders named European Inventor Award finalists

May 16, 2024

Replacement – Board Change

May 13, 2024

Update on financial status

April 30, 2024

Board Change

April 30, 2024

Faron confirms plans under new leadership

April 16, 2024

Approval of Warrant Terms and Conditions

April 8, 2024

Decisions of the Board of Directors

April 8, 2024

Appointment of Chief Executive Officer

April 8, 2024

Results of the Annual General Meeting

April 5, 2024

Announcement of Placing

April 4, 2024

Issue of Warrants to IPF Funding Update

March 28, 2024

Faron´s Annual Report 2023

March 26, 2024

Additional Positive Data from Phase 1 of BEXMAB

March 18, 2024

Faron to Host BEXMAB Webcast

March 14, 2024

Notice of Annual General Meeting 2024

March 13, 2024

Financial Statement January 1 to December 31 2023

March 13, 2024

Binding commitments for convertible loans

March 4, 2024

Replacement - Update to 2024 Financial Calendar

February 28, 2024

Update to Faron’s Financial Calendar for 2024

February 27, 2024

Continued Negotiations Regarding Events of Default

February 21, 2024

Events of Default

February 19, 2024

Further re: Exercise of options

January 31, 2024

BEXMAB Insights into Patient Profiles

January 25, 2024

Exercise of options - Issue of equity

January 19, 2024

First Patient Dosed in Ph 2 of the BEXMAB Trial

January 9, 2024

Presentation at J.P. Morgan Healthcare Conference

January 3, 2024

Decks in 2024